Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMIXMQE)

• Drug Name: GAP T cells Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMIXMQE

Molecule-Related Drug Atlas

Drug(s) Targeting Glypican-3 (GPC3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RG7686	DM6CNFW	Hepatocellular carcinoma	2C12.02	Phase 2	[2]
GPC-3298306	DMOHAS2	Hepatocellular carcinoma	2C12.02	Phase 2	[3]
Codrituzumab	DMDWG36	Hepatic metastasis	2D80	Phase 2	[4]
GC33	DMXTD74	Hepatocellular carcinoma	2C12.02	Phase 2	[2]
SAR444200	DM7J5H0	Aggressive cancer	2A00-2F9Z	Phase 2	[5]
GPC3-CART cells	DMGN679	Hepatocellular carcinoma	2C12.02	Phase 1/2	[6]
TAI-GPC3-CART cells	DMCFSZ5	Hepatocellular carcinoma	2C12.02	Phase 1/2	[7]
CAR-T cells targeting GPC3	DM6H1MQ	Hepatocellular carcinoma	2C12.02	Phase 1/2	[8]
Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs	DMDO6J1	Hepatocellular carcinoma	2C12.02	Phase 1/2	[9]
CAR-T cells targeting Glypican-3 (GPC3)	DMDSKR2	Hepatocellular carcinoma	2C12.02	Phase 1/2	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glypican-3 (GPC3)	TTJTSX4	GPC3_HUMAN	CAR-T-Cell-Therapy	[1]

References

• [1] ClinicalTrials.gov (NCT02932956) Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)
• [2] First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2013 Feb 15;19(4):920-8.
• [3] Usefulness of a novel oncofetal antigen, glypican-3, for diagnosis and immunotherapy of hepatocellular carcinoma. Nihon Rinsho Meneki Gakkai Kaishi. 2008 Oct;31(5):383-91.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Clinical pipeline report, company report or official report of Sanofi
• [6] ClinicalTrials.gov (NCT03130712) A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART)
• [7] ClinicalTrials.gov (NCT02715362) A Study of GPC3 Redirected Autologous T Cells for Advanced HCC
• [8] ClinicalTrials.gov (NCT02959151) A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
• [9] ClinicalTrials.gov (NCT03084380) Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC)
• [10] ClinicalTrials.gov (NCT02723942) CAR-T Cell Immunotherapy for HCC Targeting GPC3